MEDARTIS N overview

Medartis Holding AG / Key word(s): Annual Results/Forecast Medartis delivers 12% core sales growth in 2024 and improves its core EBITDA margin from 17% to 19% 18-March-2025 / 06:59 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. Core sales 1 in 2024 grew 11.7% (CER)...

Medartis Holding AG / Key word(s): Half Year Results Medartis reports 13% revenue growth on Group level, driven by strong regional growth in the US (21%) and EMEA (18%) –improvement of EBITDA* margin to 17% 20-Aug-2024 / 07:05 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this...

Medartis Holding AG / Key word(s): Personnel Basel, 9th July 2024 Matthias Schupp appointed as CEO of Medartis 09-Jul-2024 / 06:59 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. Medartis today announced that its Board has appointed Matthias Schupp to the position of...

Medartis Holding AG / Key word(s): Personnel Basel, 11th June 2024 Medartis announces resignation of CEO Christoph Brönnimann 11-Jun-2024 / 06:59 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. Medartis announces that its CEO, Christoph Brönnimann, has decided to...

Medartis Holding AG / Key word(s): Bond/Financing Medartis successfully places CHF 115.8 million convertible bonds due 2031 04-Apr-2024 / 07:25 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES,...

Medartis Holding AG / Key word(s): Financing/Issue of Debt Medartis launches senior convertible bond offering in a private placement of approximately CHF 115 million due 2031 03-Apr-2024 / 17:43 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. Basel, 3 April 2024:...

Medartis Holding AG / Key word(s): Annual Results Medartis increases sales by 21% (CER) and improves its underlying EBITDA margin to 16% 12-March-2024 / 06:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. Demonstrating further market share gains, full-year 2023...

Medartis Holding AG / Key word(s): Half Year Results Medartis on track with 16% internal growth after 6 months 15-Aug-2023 / 06:58 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. Net sales in H1 2023 increased by 20.8% (CER) to CHF 103.3 million Internal sales...